18:49 , May 12, 2017 |  BC Week In Review  |  Company News

Adamas, HCR in $100M royalty deal

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) will receive a loan worth up to $100 million via a royalty note deal with HealthCare Royalty Partners (Stamford, Conn.). The company is to receive $35 million up front and $65...
23:13 , May 11, 2017 |  BC Extra  |  Financial News

Adamas, HCR in $100M royalty deal

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) is to receive a loan worth up to $100 million via a royalty note deal with HealthCare Royalty Partners . The company is to receive $35 million up front and $65...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Allergan, Adamas Pharmaceuticals, Amneal Pharmaceuticals deal

Allergan and Adamas granted Amneal rights to market on Jan. 1, 2025, generic versions of Namzaric memantine/donepezil to treat moderate to severe dementia in Alzheimer’s disease patients stabilized on 10 mg of once-daily donepezil. Amneal...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

Namzaric memantine ER/donepezil regulatory update

FDA approved an NDA from Actavis’ Forest Laboratories Inc. subsidiary for Namzaric memantine extended-release/donepezil to treat moderate to severe dementia of the Alzheimer’s type in patients stabilized on memantine and donepezil. Actavis expects to launch...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Clinical News

Memantine ER/donepezil regulatory update

FDA accepted for review an NDA from Forest for a once-daily, fixed-dose combination of memantine extended release (ER) and donepezil to treat moderate to severe dementia of the Alzheimer's type. The acceptance triggered a $25...
00:26 , Apr 11, 2014 |  BC Extra  |  Financial News

Adamas raises $48 million in IPO

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) raised $48 million through the sale of 3 million shares at $16 in an IPO underwritten by Credit Suisse; Piper Jaffray; William Blair; and Needham. The price -- at the low...
00:34 , Mar 27, 2014 |  BC Extra  |  Financial News

Adamas sets IPO range

CNS company Adamas Pharmaceuticals Inc. (Emeryville, Calif.) amended its IPO on NASDAQ and now plans to sell 3 million shares at $16-$18. At the $17 midpoint, the company would raise $51 million and be valued...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Clinical News

Memantine ER/donepezil regulatory update

Forest Labs submitted an NDA for a once-daily, fixed-dose combination of memantine extended release (ER) and donepezil to treat moderate to severe dementia of the Alzheimer's type. Forest Labs and Adamas developed the combination under...
00:51 , Mar 6, 2014 |  BC Extra  |  Financial News

Adamas files for IPO

CNS company Adamas Pharmaceuticals Inc. (Emeryville, Calif.) filed to raise up to $69 million in an IPO on NASDAQ underwritten by Credit Suisse; Piper Jaffray; William Blair; and Needham. This year, Adamas plans to start...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Adamas Pharmaceuticals, Forest Laboratories deal

Adamas said it received $40 million in milestones from Forest under a 2012 deal to develop and commercialize Adamas' memantine ER/donepezil ( MDX-8704 ) in the U.S. to treat moderate to severe Alzheimer's disease. Adamas...